

B1
Amend
C1

sufficient to sustain momentum in transmission from a delivery device to a target site
within an eye.

B2

4. (Amended) A dosage form according to Claim [3] 1 wherein the jet or each droplet is of a size sufficient to sustain momentum along a substantially horizontal path 5 cms in length from a discharge velocity of up to 25 m/sec from the delivery system.

B3

12. (Amended) A method of increasing the ocular bioavailability of an ophthalmologically active compound, wherein the compound is provided in suspension or solution in a body of ophthalmic treatment liquid in a dosage form comprising the liquid as a jet and/or stream of droplets, the jet and/or each droplet being of a size sufficient to sustain momentum in transmission from a delivery device to a target site within an eye, the jet and/or droplets having a mean diameter in the range 20 μm to 1000 μm .

B4

16. (Amended) A dosage form according to Claim [3] 1 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .

17. (Amended) A dosage form according to Claim [3] 1 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .